The National Academies found limited evidence that THC capsules reduce tic severity — 'limited' meaning small trials with positive signals rather than proven therapy. German research groups drove most of it; patient-reported outcomes run ahead of the trial base, as usual. For adults whose tics resist standard treatments (alpha-agonists, antipsychotics, CBIT therapy), a supervised cannabis trial is a reasonable conversation.
The same honesty applies in reverse: THC's cognitive effects matter for students and working adults, dosing for tic control is individual and experimental, and behavioral therapy (CBIT) remains the best-evidenced non-drug treatment. Adolescent Tourette patients face the usual developing-brain calculus — physicians will be conservative, correctly.
The information on this site is for educational purposes only and is not medical or legal advice. Cannabis use carries risks; consult a licensed physician about whether medical cannabis is appropriate for you. Federal status (as of June 2026): marijuana dispensed under state medical licenses and FDA-approved cannabis products are Schedule III controlled substances; all other marijuana remains Schedule I under U.S. federal law.